Top Markets
Coin of the day
Caliway Biopharmaceuticals Co. L Caliway Biopharmaceuticals Co. L

Caliway Biopharmaceuticals Co. L

6919
Rang in Aktien #3556
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aktienkurs
$3.28
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$5.10B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-49.70%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)

Kategorie

Kursverlauf für Caliway Biopharmaceuticals Co. L (6919)
Höchster Schlusskurs: $3.30 am 2026-07-01

Niedrigster Schlusskurs: $0.20 am 2022-12-01
Kursverlauf der Aktie von Caliway Biopharmaceuticals Co. L von 2022 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -13.85%
2025 190.26%
2024 181.33%
2023 210.73%
2022 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$553.09 42.85%
US
$1.02K 44.02%
NL
$158.64 541.49%
US
$122.12 -12.63%
AU
$772.27 7.33%
CH